AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

March 21, 2013

 

AstraZeneca today announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Messenger RNA therapeutics™ are an entirely new treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

April 10, 2012

Initiative combines Merck’s drug development expertise with Flagship’s experience in building early stage companies

National Institute of Nursing Research Uses Quanterix’s Simoa Technology to Identify the Significance of Key Protein in Long-term Complications Caused by Traumatic Brain Injury

National Institute of Nursing Research Uses Quanterix’s Simoa Technology to Identify the Significance of Key Protein in Long-term Complications Caused by Traumatic Brain Injury

August 3, 2015

Study identifies the correlation of tau accumulation in military personnel to those who experienced long-term neurological symptoms after a TBI; findings to be used to identify patients who are most at risk

Quanterix Named Final Winner of NFL and GE Head Health Challenge I

Quanterix Named Final Winner of NFL and GE Head Health Challenge I

July 23, 2015

GE and the NFL award Quanterix with $500,000 grant to fund advancements in measuring the long-term effects of brain injury in athletes using its Simoa technology

Denali Therapeutics Appoints Carole Ho, M.D., as Chief Medical Officer and Head of Development

Denali Therapeutics Appoints Carole Ho, M.D., as Chief Medical Officer and Head of Development

July 22, 2015

SOUTH SAN FRANCISCO, Calif., July 22, 2015 /PRNewswire-USNewswire/ -- Denali Therapeutics Inc. ("Denali"), a biotechnology company focused on developing effective therapies for neurodegenerative diseases, announced today that Carole Ho, M.D., has joined the company as Chief Medical Officer and Head of Development. In this role, Dr. Ho will lead the translational and clinical development activities at Denali and serve on the Executive Leadership Team.

Joule Appoints Peter Matrai CFO, Biofuels industry veteran brings expertise in commercialization of new technologies

Joule Appoints Peter Matrai CFO, Biofuels industry veteran brings expertise in commercialization of new technologies

July 22, 2015

Bedford, Mass -- Joule, the pioneer of liquid fuels from recycled CO2, today announced the appointment of Peter Matrai as Senior Vice President and Chief Financial Officer. He joins the company with nearly 20 years of experience in finance, global strategy and corporate development, including a decade spent in the biofuels sector for BP.

Red Rock Reaches Agreement with FedEx Express to Provide Biofuels for Renewable, Low-Carbon Jet Fuel

Red Rock Reaches Agreement with FedEx Express to Provide Biofuels for Renewable, Low-Carbon Jet Fuel

July 21, 2015

FORT COLLINS, Colo.--(BUSINESS WIRE)--Red Rock Biofuels LLC, a pioneer in renewable biofuels, announced today that it will produce approximately three million gallons of low-carbon, renewable jet fuel per year for FedEx Express, a subsidiary of FedEx Corp. (NYSE:FDX). The agreement runs through 2024, with first delivery expected in 2017. FedEx joins Southwest Airlines in purchasing Red Rock’s total available volume of jet fuel.

Editas Medicine Appoints Andrew Hack, M.D., Ph.D., as Chief Financial Officer

Editas Medicine Appoints Andrew Hack, M.D., Ph.D., as Chief Financial Officer

July 1, 2015

-- Experienced Healthcare Finance Leader Joins Leadership Team to Help Drive Continued Growth --

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Editas Medicine, a leading genome editing company, today announced the appointment of Andrew Hack, M.D., Ph.D., as chief financial officer. Dr. Hack brings to Editas a deep understanding of capital markets, strong relationships across the financial community and more than a decade of experience analyzing the successes and failures of biopharmaceutical companies.

Seres Therapeutics, Inc. Announces Pricing of Initial Public Offering

Seres Therapeutics, Inc. Announces Pricing of Initial Public Offering

June 25, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. today announced the pricing of its initial public offering of 7,430,555 shares of common stock at a public offering price of $18.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Seres Therapeutics. In addition, Seres Therapeutics granted the underwriters a 30-day option to purchase up to an additional 1,114,583 shares of common stock from the company at the public offering price.

Agios Announces First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation

Agios Announces First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation

June 24, 2015

 – Third IDH Mutant Inhibitor to Enter Clinical Trials –

– Brain Penetration and Pan-IDHm Inhibition Broaden Development Options for IDH Mutant-Positive Cancers, Including Gliomas –